What smart money is saying about Neogenomics, Inc.
NEO
No fund has written a full thesis on Neogenomics, Inc. in our archive, but 2 fund letters report a position in it — most recently Brown Advisory US Smaller Companies Fund in June 2025.
Get an email when a fund writes about it
2
Reported positions
1
Bought
1
Sold
2
Letters
Position history
Between Q1 2025 and Q2 2025, 2 fund letters reported a position in Neogenomics, Inc. — 1 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2025 | 1 | 0 | 1 | 0 |
| Q1 2025 | 1 | 1 | 0 | 0 |
Fund activity · 2 positions · 2 moves
- June 2025
“Neogenomics, Inc. (NEO) was sold after the surprising timing of the departure of its CEO.”
Neogenomics, Inc. - March 2025
“During1Q25, we added to healthcare, which is now our second largest overweight. NeoGenomics, Inc. was the largest addition in healthcare, as we sought to take advantage of weakness during the quarter.”
Neogenomics, Inc.
Read the letters behind these Neogenomics, Inc. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger